Condition: Myelodysplastic Syndromes · Ferroptosis · Sponsor: University Hospital, Bordeaux
Myelodysplastic syndromes (MDS) are clonal diseases of hematopoietic stem cells (HSC) characterized by dysplastic and inefficient hematopoiesis related to excessive progenitor cell death. Ferroptosis is a recently described cell death mechanism and we think that it could be a major player in the pathophysiology of MDS, involved in the cell death that characterizes these diseases and contributing to cytopenias. The study aims to demonstrate that there is a significant activation of this phenomenon in MDS patients compared to a population of subjects without MDS.
This description comes directly from the study's public registry record.
Victor-Emmanuel BRETT · 0556774357 · victor.brett@chu-bordeaux.fr
Charles DUSSIAU · charles.dussiau@chu-bordeaux.fr
Always discuss trial participation with your own doctor first.
| CHU de Bordeaux, Laboratoire d'Hématologie | Pessac, France | Not Yet Recruiting |
| CHU de Bordeaux, Service de Médecine Interne | Pessac, France | Not Yet Recruiting |
| CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire | Pessac, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05924074